Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland by Sanchez-Padilla, E et al.
correspondence
n engl j med 372;12 nejm.org march 19, 2015 1181
2. Chambaere K, Bilsen J, Cohen J, Onwuteaka-Philipsen BD, 
Mortier F, Deliens L. Trends in medical end-of-life decision 
making in Flanders, Belgium 1998-2001-2007. Med Decis Mak-
ing 2011;31:500-10.
3. Belgian Official Collection of the Laws. The Belgian Act 
on Euthanasia of May 28th 2002. Ethical Perspect 2002;9: 
182-8.
4. Onwuteaka-Philipsen BD, Brinkman-Stoppelenburg A, Pen-
ning C, de Jong-Krul GJ, van Delden JJ, van der Heide A. Trends 
in end-of-life practices before and after the enactment of the 
euthanasia law in the Netherlands from 1990 to 2010: a repeated 
cross-sectional survey. Lancet 2012;380:908-15.
DOI: 10.1056/NEJMc1414527
Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF  
in Swaziland
To the Editor: Tuberculosis is a major global 
health problem that has worsened with the in-
creasing emergence of Mycobacterium tuberculosis 
(MTB) complex strains that are resistant to ri-
fampin (RIF) and isoniazid. As recommended by 
the World Health Organization (WHO), the time-
ly detection of drug resistance with the use of 
rapid molecular diagnostic tests, such as the 
Xpert MTB/RIF assay (Cepheid), is essential for 
appropriate treatment of patients with tuberculo-
sis and for limiting the further spread of multi-
drug-resistant disease.1,2 
We used 24-loci mycobacterial interspersed 
repetitive unit–variable number tandem repeat 
(MIRU-VNTR) analysis and spoligotyping to 
perform classic genotypic analysis of MTB com-
plex strains from the most recent (2009) na-
tional survey of tuberculosis-drug resistance in 
Swaziland, a country with a high prevalence of 
tuberculosis (945 cases per 100,000 persons, or 
approximately 1%).3 We found that 38 of 125 
multidrug-resistant strains (30%) that were iso-
lated during the survey carried the rpoB I491F 
mutation, which confers resistance to rifampin 
(Table 1; and the Supplementary Appendix, 
available with the full text of this letter at NEJM 
.org). This mutation, which was previously re-
ported with low frequency in clinical isolates 
from Hong Kong and Australia,4 is not detected 
by the Xpert MTB/RIF assay.
Xpert MTB/RIF, a cartridge-based point-of-
care assay, is designed to identify rifampin resis-
tance mutations in an 81-bp region of rpoB (co-
dons 426 to 452). Its inability to detect the rpoB 
I491F outbreak strain raises new challenges, 
since Xpert MTB/RIF is used throughout most of 
Swaziland as the first-line diagnostic test for 
tuberculosis and for multidrug-resistant tuber-
culosis, as recommended by the WHO.5 Thus, 
the circulation of strains with the rpoB I491F 
mutation substantially reduces the sensitivity of 
Xpert MTB/RIF–based diagnosis in Swaziland 
and presumably results in underdiagnosis and 
potentially inadequate treatment. This is prob-
lematic in a country where an estimated 26% of 
adults are infected with the human immunode-
ficiency virus (HIV) and 80% of patients with 
tuberculosis are coinfected with HIV. In addi-
tion, coinfected patients are more likely than 
Table 1. Mutations in rpoB in 125 Multidrug-Resistant 
Strains from the 2009 Survey Regarding Tuberculosis-
Drug Resistance in Swaziland.*
Mutation
Strains with  
Mutation
Mutation in rpoB 
Hot-Spot Region†
no. (%)
D435F 1 (0.8) Yes
D435F, N437D 3 (2.4) D435F, yes; 
N437D, yes
D435V 1 (0.8) Yes
G442R,‡ I491F 1 (0.8) G442R, yes; 
I491F, no
H445D 7 (5.6) Yes
H445L 6 (4.8) Yes
H445Y 6 (4.8) Yes
I491F, R552C 1 (0.8) I491F, no;  
R552C, no
I491F 38 (30.4) No
QF432–433del 1 (0.8) Yes
S450L 58 (46.4) Yes
S450W 1 (0.8) Yes
Unmutated 1 (0.8) No
* Mutations are listed according to numbering for the Myco ­
bacterium tuberculosis H37Rv genome. Some strains carry 
two mutations.
† The hot-spot region of rpoB ranges from codon 426 to 
codon 452.
‡ This is a heterozygous single-nucleotide polymorphism.
The New England Journal of Medicine 
Downloaded from nejm.org on March 25, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 372;12 nejm.org march 19, 20151182
corrections
HIV-negative patients to have multidrug-resis-
tant infection.3 Further transmission of the rpoB 
I491F strain in this population is another likely 
consequence.
On the basis of these findings, Xpert MTB/
RIF testing may be unreliable in Swaziland, 
since it can miss a substantial percentage of 
strains that may be resistant to rifampin. More 
studies are needed to assess the prevalence of 
similar mutations in neighboring countries.
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